BioCorRx Q3: Cash Down to $18,233, Going Concern Doubt Reaffirmed
BICX sits 39% above its 52-week low of $0.152 on light trading volume (0.2× avg).
Summary
BioCorRx's Q3 2026 10-Q shows cash of only $18,233, a $8.65M working capital deficit, negative quarterly revenue, and a reaffirmed going-concern warning — survival now depends on insider loans and new equity sales.
Key Events · Earnings and Guidance · BICX
-
Going Concern Doubt Reaffirmed
As of September 30, 2026, the company held cash of $18,233 and a working capital deficit of $8,652,785; management states substantial doubt about continuing as a going concern for the next twelve months.
-
Quarterly Revenue Turns Negative
Q3 2026 net revenue was $(40,348) versus $213,910 a year earlier, as the USWM distribution channel was wound down and prior-quarter chargeback adjustments exceeded current gross sales.
-
Cash Burn and Insider Funding
Nine-month operating cash use was $1,052,875; during 2026 the company raised $650,000 from stock subscriptions and $404,904 of related-party promissory note advances from President Louis Lucido.
-
Material Weaknesses Disclosed
Management identified material weaknesses in internal control over financial reporting — undocumented policies, insufficient GAAP expertise on complex transactions, and too few staff for segregation of duties — and concluded disclosure controls were not effective.
Analysis · BICX · Industrial Applications And Services
BioCorRx closed Q3 with just $18,233 of cash against a working capital deficit of $8,652,785, and management again flags substantial doubt about the company's ability to continue as a going concern for the next twelve months. Revenue for the quarter was actually negative $(40,348) as the USWM LUCEMYRA distribution channel was wound down and prior-quarter chargebacks exceeded current sales. Operations are not funding the company; insider advances — $404,904 from President Louis Lucido during 2026 — and equity sales to directors are. With a nine-month operating cash burn of $1,052,875 and no committed financing, another dilutive raise or further insider loans are the only visible paths to keep the lights on.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BICX was trading at $0.21 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $0.15 to $1.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.